FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

Overview

Journal World J Oncol

Specialty Oncology

Date 2017 Oct 7

PMID 28983344

Citations 3

Authors

Andrea Botticelli

Federica Mazzuca

Marina Borro

Eva Mazzotti

Marco La Torre

Adriana Bonifacino

Francesca Romana Ciabatta

Giovanna Gentile

Chiara Maddalena

Maurizio Simmaco

Paolo Marchetti

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients.

Methods: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed.

Results: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012).

Conclusions: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.

Citing Articles

Role of Fcγ receptors in HER2-targeted breast cancer therapy.

Musolino A, Gradishar W, Rugo H, Nordstrom J, Rock E, Arnaldez F J Immunother Cancer. 2022; 10(1).

PMID: 34992090 PMC: 8739678. DOI: 10.1136/jitc-2021-003171.

Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells.

Wieckowski S, Avenal C, Orjalo Jr A, Gygax D, Cymer F Front Immunol. 2020; 11:552596.

PMID: 33193318 PMC: 7658677. DOI: 10.3389/fimmu.2020.552596.

A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism.

Mahaweni N, Olieslagers T, Rivas I, Molenbroeck S, Groeneweg M, Bos G Sci Rep. 2018; 8(1):15983.

PMID: 30374078 PMC: 6206037. DOI: 10.1038/s41598-018-34258-1.

References

Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K . FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2010; 22(6):1302-1307. DOI: 10.1093/annonc/mdq585. View

Robertson M, Ritz J . Biology and clinical relevance of human natural killer cells. Blood. 1990; 76(12):2421-38. View

Parren P, Warmerdam P, Boeije L, Arts J, Westerdaal N, Vlug A . On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. 1992; 90(4):1537-46. PMC: 443201. DOI: 10.1172/JCI116022. View

Kim J, Kim J, Im S, Kim Y, Han H, Kim J . ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology. 2012; 83(4):218-27. DOI: 10.1159/000341359. View

Sliwkowski M, Lofgren J, Lewis G, Hotaling T, Fendly B, Fox J . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26(4 Suppl 12):60-70. View

Koene H, Kleijer M, Algra J, Roos D, von dem Borne A, de Haas M . Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997; 90(3):1109-14. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

Carson W, Parihar R, Lindemann M, Personeni N, Dierksheide J, Meropol N . Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001; 31(10):3016-25. DOI: 10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j. View

Shields R, Namenuk A, Hong K, Meng Y, RAE J, Briggs J . High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2000; 276(9):6591-604. DOI: 10.1074/jbc.M009483200. View

10.

Jaime-Ramirez A, Mundy-Bosse B, Kondadasula S, Jones N, Roda J, Mani A . IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol. 2011; 186(6):3401-9. PMC: 3593307. DOI: 10.4049/jimmunol.1000328. View

11.

Omar A, Shibata H, Yasunami M, Yamazaki A, Ofori M, Akanmori B . The rs150311303 polymorphism in FcγRIIa enhances IgG binding capacity. Scand J Immunol. 2012; 76(2):167-74. DOI: 10.1111/j.1365-3083.2012.02715.x. View

12.

Warmerdam P, van de Winkel J, Vlug A, Westerdaal N, Capel P . A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991; 147(4):1338-43. View

13.

Hogarth P, Pietersz G . Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012; 11(4):311-31. DOI: 10.1038/nrd2909. View

14.

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C . Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006; 94(2):259-67. PMC: 2361112. DOI: 10.1038/sj.bjc.6602930. View

15.

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G . Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26(11):1789-96. DOI: 10.1200/JCO.2007.14.8957. View

16.

Salmon J, Edberg J, Brogle N, Kimberly R . Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest. 1992; 89(4):1274-81. PMC: 442988. DOI: 10.1172/JCI115712. View

17.

Mellor J, Brown M, Irving H, Zalcberg J, Dobrovic A . A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013; 6:1. PMC: 3549734. DOI: 10.1186/1756-8722-6-1. View

18.

Hurvitz S, Betting D, Stern H, Quinaux E, Stinson J, Seshagiri S . Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012; 18(12):3478-86. PMC: 3821872. DOI: 10.1158/1078-0432.CCR-11-2294. View